Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
Zhang, Y.; Xu, M.; Yuan, J.; Hu, Z.; Jiang, J.; Sun, Y.; Huang, J.; Wang, Y.; Wang, B.; Shen, J.; Long, M.; Fan, Y.; Montone, K. T.; Tanyi, J. L.; Kim, S. H.; Tavana, O.; Vonderheide, R. H.; Chan, H. M.; Domchek, S. M.; Hu, X.; Zhang, L.
Show abstract
Therapeutic epigenetic modulation is currently being evaluated in the clinic to sensitize homologous recombination (HR)-proficient tumors to PARP inhibitors. To broaden its clinical applicability and identify more effective combination strategies, we conducted a drug screen combining PARP inhibitors with 74 well-characterized epigenetic modulators targeting five major classes of epigenetic enzymes. Notably, both type I PRMT inhibitors and PRMT5 inhibitors scored highly in combination efficacy and clinical prioritization. PRMT inhibition significantly enhanced PARP inhibitor-induced DNA damage in HR-proficient ovarian and breast cancer cells. Mechanistically, PRMT suppression downregulates DNA damage repair genes and BRCAness-associated pathways, while also modulating intrinsic innate immune responses within cancer cells. Integrative analysis of large-scale genomic and functional datasets from TCGA and DepMap further supports PRMT1, PRMT4, and PRMT5 as promising therapeutic targets in oncology. Importantly, dual inhibition of PRMT1 and PRMT5 synergistically sensitizes tumors to PARP inhibitors. Collectively, our findings provide strong rationale for the clinical development of PRMT and PARP inhibitor combinations in HR-proficient ovarian and breast cancers.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM 96%
- The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. 96%
- An integrative oncogene-dependency map identifies unique vulnerabilities of oncogenic EGFR, KRAS, and RIT1 in lung cancer 96%
Similar papers in this journal
- CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis 97%
- EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes 96%
- Aberrant transcript usage induces homologous recombination deficiency and predicts therapeutic responses 96%
Similar papers in this journal
- Flap endonuclease 1 repairs DNA-protein crosslinks via ADP-ribosylation 94%
- An in vivo screen identifies NAT10 as a master regulator of brain metastasis 94%
- Select EZH2 inhibitors enhance the viral mimicry effects of DNMT inhibition through a mechanism involving calcium-calcineurin-NFAT signaling 94%
Similar papers in this journal
Similar papers in this journal
- Targeting KRAS-mutant stomach/colorectal tumours by disrupting the ERK2-p53 complex 96%
- Guiding ATR and PARP inhibitor combinations with chemogenomic screens 96%
- Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.